These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2904925)

  • 1. Renal tolerance of fleroxacin in healthy volunteers.
    Mondorf AW; Buch A; Steinbacher G; Rüdel C; Falkenberg FW
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():179-89. PubMed ID: 2904925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
    Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
    Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and multiple dose pharmacokinetics of fleroxacin.
    Weidekamm E; Portmann R; Partos C; Dell D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
    Parent M; St-Laurent M; LeBel M
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
    Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
    Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation on renal tolerability of ciprofloxacin with tests based on monoclonal antibodies.
    Falkenberg FW; Mondorf AW
    Infection; 1988; 16 Suppl 1():S69-75. PubMed ID: 3372030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of alanine aminopeptidase excretion as a test of gentamicin nephrotoxicity.
    Davey PG; Geddes AM; Cowley DM
    J Antimicrob Chemother; 1983 May; 11(5):455-65. PubMed ID: 6135686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis.
    Pust RA; Ackenheil-Köppe HR; Weidner W; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():227-30. PubMed ID: 3144543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of fleroxacin in man.
    Sörgel F; Seelmann R; Naber K; Metz R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
    Sorgel F; Metz R; Naber K; Seelmann R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin.
    Whitby M; Angus L; Nimmo G; Hill V
    Chemotherapy; 1996; 42(6):468-72. PubMed ID: 8957583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
    Wolfhagen MJ; Hoepelman AI; Verhoef J
    Antimicrob Agents Chemother; 1990 Mar; 34(3):409-12. PubMed ID: 2110437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal handling of fleroxacin in rabbits, dogs, and humans.
    Shiba K; Saito A; Shimada J; Hori S; Kaji M; Miyahara T; Kusajima H; Kaneko S; Saito S; Ooie T
    Antimicrob Agents Chemother; 1990 Jan; 34(1):58-64. PubMed ID: 2109576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/tobramycin combination in volunteers.
    Mondorf AW; Heynold FT; Scherberich JE; Hess H; Schoeppe W
    Infection; 1983; 11 Suppl 1():S57-62. PubMed ID: 6131873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.
    Bowie WR; Willetts V; Jewesson PJ
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1778-82. PubMed ID: 2511802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.